Scholarlink

<p>The recently proposed body-first and brain-first subtypes are classified based on the initial localization of α-synuclein inclusions. This study investigated plasma biomarkers and cerebral glucose metabolism characteristics in putative brain-first and body-first subtypes in PD subjects. PD patients without possible RBD (PD<sup>pRBD–</sup>) (<i>n</i> = 58) and with possible RBD symptoms discovered before motor symptoms (PD<sup>pRBD+</sup>) (<i>n</i> = 43) were recruited. Single-molecule array (SimoA) was used for measuring plasma biomarkers, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), Tau and phosphorylated-tau 181 (pTau-181). All participants underwent <sup>18</sup>F-fluorodeoxyglucose (FDG) PET scans. Compared to PD<sup>pRBD–</sup> patients, PD<sup>pRBD+</sup> patients exhibited significantly increased plasma GFAP levels and reduced <sup>18</sup>F-FDG uptake in cortical regions. Notably, plasma GFAP and NfL levels correlated with cerebral glucose metabolism in PD<sup>pRBD–</sup> patients. Our study identified the association between plasma GFAP and NfL levels and cerebral glucose metabolism in PD<sup>pRBD–</sup> patients. Further large-scale longitudinal studies are required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma GFAP and NfL associate with cerebral glucose metabolism in putative brain-first and body-first Parkinson’s disease subtypes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月22日

查看全文
  • Shiyu Li,
  • Fangyang Jiao,
  • Xiuyuan Li,
  • Zhiheng Xu,
  • Tianyu Hu,
  • Xiaoniu Liang,
  • Jianjun Wu,
  • Jian Wang,
  • Chuantao Zuo,
  • Yilin Tang

摘要

The recently proposed body-first and brain-first subtypes are classified based on the initial localization of α-synuclein inclusions. This study investigated plasma biomarkers and cerebral glucose metabolism characteristics in putative brain-first and body-first subtypes in PD subjects. PD patients without possible RBD (PDpRBD–) (n = 58) and with possible RBD symptoms discovered before motor symptoms (PDpRBD+) (n = 43) were recruited. Single-molecule array (SimoA) was used for measuring plasma biomarkers, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), Tau and phosphorylated-tau 181 (pTau-181). All participants underwent 18F-fluorodeoxyglucose (FDG) PET scans. Compared to PDpRBD– patients, PDpRBD+ patients exhibited significantly increased plasma GFAP levels and reduced 18F-FDG uptake in cortical regions. Notably, plasma GFAP and NfL levels correlated with cerebral glucose metabolism in PDpRBD– patients. Our study identified the association between plasma GFAP and NfL levels and cerebral glucose metabolism in PDpRBD– patients. Further large-scale longitudinal studies are required.